The Role of MLL-AF9 in Acute Myeloid Leukemia

MLL-AF9 在急性髓系白血病中的作用

基本信息

  • 批准号:
    7698026
  • 负责人:
  • 金额:
    $ 37.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-17 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

Hematopoietic as well as leukemic stem cells (HSC/LSC) are dependent on interactions with extracellular matrix, soluble factors and cellular components of the bone marrow (BM) microenvironment for their survival. These interactions are hypothesized to promote the quiescence of the stem cell and their retention in the niche and influence the decisions regarding symmetric versus asymmetric self-renewal divisions. The signals that contribute to these decisions are just now being identified and likely involve the classical molecular pathways shown to be important in stem cells, including WNT/catenin, Notch, KitL/Kit and SDF/CXCR4 signaling. Each of these signals impacts directly or indirectly on the Rho family of small GTPase proteins, including the Rac family. These proteins play an essential role in the retention of HSC in the niche and in the survival, proliferation and differentiation decisions that are critical for sustaining hematopoiesis and maintaining the integrity of the stem cell compartment. We have recently demonstrated that activated Rac is increased in a novel model of human leukemia. In this model, the MLL-AF9 (MA9) leukemia oncogene is used to transform primary human CD34+ cells and promotes a rapid acute myeloid leukemia (AML) in immunodeficient mice. Suppression of Rac-GTP formation using the Rac inhibitor NSC23766, or shRNA knockdown of Rac expression, could effectively promote apoptosis and suppress proliferation under conditions where little or no inhibitory effect could be detected on normal human CD34+ cord blood cells. The inhibition of Rac and the induction of apoptosis correlate with the loss of Bcl protein expression, especially of Bcl-xL, which is an identified downstream target of Rac2 signaling. We propose to use our newly developed leukemia model to study the role of Rac signaling in MLL leukemia cells using in vitro assays measuring well-characterized phenotypes associated with Rac activity, including migration, survival, adhesion and proliferation (Aim1). We will extend these results in vivo using a xenograft system and a pharmacologic as well as RNAi approach to inhibit Rac activity as well as Bcl-xL function (Aim 2). This combinatorial approach should enable us to determine the importance of the Rac signaling pathway in leukemia and begin to dissect the specific mechanisms involved in the Rac addiction in MA9 AML. RELEVANCE (See instructions): We have recently shown that human blood stem cells can be induced to make leukemia upon introduction
造血干细胞和白血病干细胞(HSC/LSC)的生存依赖于与骨髓微环境中的细胞外基质、可溶性因子和细胞成分的相互作用。这些相互作用被认为是为了促进干细胞的静止和它们在利基中的保留,并影响关于对称或不对称自我更新分裂的决定。参与这些决定的信号现在才刚刚被识别出来,可能涉及在干细胞中很重要的经典分子通路,包括WNT/Catenin、Notch、KitL/Kit和SDF/CXCR4信号。这些信号中的每一个都直接或间接地影响Rho家族的小GTP酶蛋白,包括RAC家族。这些蛋白质在干细胞在巢内的保留以及生存、增殖和分化决策中起着至关重要的作用,而这些决策对于维持造血和维持干细胞室的完整性至关重要。我们最近证明,在一种新的人类白血病模型中,激活的RAC增加。在这个模型中,MLL-AF9(MA9)白血病癌基因被用来转化原代人类CD34+细胞,并在免疫缺陷小鼠中促进快速急性髓系白血病(AML)。用RAC抑制剂NSC23766抑制RAC-GTP的形成,或shRNA抑制RAC的表达,在对正常人CD34+脐血细胞几乎没有抑制作用的条件下,可以有效地促进细胞凋亡和抑制细胞增殖。Rac的抑制和细胞凋亡的诱导与Bcl2蛋白表达的缺失密切相关,尤其是作为rac2信号下游靶点的Bclxl。我们建议使用我们新开发的白血病模型来研究Rac信号在MLL白血病细胞中的作用,方法是通过体外测试与Rac活性相关的表型,包括迁移、存活、黏附和增殖(Aim1)。我们将使用异种移植系统和药理学以及RNAi方法在体内扩展这些结果,以抑制RAC活性和Bcl-XL功能(目标2)。这种结合的方法应该使我们能够确定RAC信号通路在白血病中的重要性,并开始剖析MA9 AML中RAC成瘾的具体机制。相关性(参见说明书):我们最近证明,人类血液干细胞在引入后可以被诱导成白血病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES C MULLOY其他文献

JAMES C MULLOY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES C MULLOY', 18)}}的其他基金

Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
  • 批准号:
    9290731
  • 财政年份:
    2017
  • 资助金额:
    $ 37.09万
  • 项目类别:
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
  • 批准号:
    10115634
  • 财政年份:
    2017
  • 资助金额:
    $ 37.09万
  • 项目类别:
Leukemia stem cell polarity and differentiation therapy
白血病干细胞极性与分化治疗
  • 批准号:
    10227111
  • 财政年份:
    2017
  • 资助金额:
    $ 37.09万
  • 项目类别:
Genotype and phenotype of chemoresistant AML
化疗耐药性 AML 的基因型和表型
  • 批准号:
    8618872
  • 财政年份:
    2013
  • 资助金额:
    $ 37.09万
  • 项目类别:
Genotype and phenotype of chemoresistant AML
化疗耐药性 AML 的基因型和表型
  • 批准号:
    8528938
  • 财政年份:
    2013
  • 资助金额:
    $ 37.09万
  • 项目类别:
Targeting Cdc42 in leukemia stem cells
靶向白血病干细胞中的 Cdc42
  • 批准号:
    8607160
  • 财政年份:
    2010
  • 资助金额:
    $ 37.09万
  • 项目类别:
Targeting Cdc42 in leukemia stem cells
靶向白血病干细胞中的 Cdc42
  • 批准号:
    8042683
  • 财政年份:
    2010
  • 资助金额:
    $ 37.09万
  • 项目类别:
Targeting Cdc42 in leukemia stem cells
靶向白血病干细胞中的 Cdc42
  • 批准号:
    8213615
  • 财政年份:
    2010
  • 资助金额:
    $ 37.09万
  • 项目类别:
Targeting Cdc42 in leukemia stem cells
靶向白血病干细胞中的 Cdc42
  • 批准号:
    8433225
  • 财政年份:
    2010
  • 资助金额:
    $ 37.09万
  • 项目类别:
The Role of CBFb-MYH11 in Acute Myeloid Leukemia
CBFb-MYH11 在急性髓系白血病中的作用
  • 批准号:
    7019382
  • 财政年份:
    2006
  • 资助金额:
    $ 37.09万
  • 项目类别:

相似海外基金

How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y004841/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
  • 批准号:
    BB/Y001427/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y005414/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
  • 批准号:
    10669829
  • 财政年份:
    2023
  • 资助金额:
    $ 37.09万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10587090
  • 财政年份:
    2023
  • 资助金额:
    $ 37.09万
  • 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
  • 批准号:
    10821599
  • 财政年份:
    2023
  • 资助金额:
    $ 37.09万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10841832
  • 财政年份:
    2023
  • 资助金额:
    $ 37.09万
  • 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
  • 批准号:
    10532480
  • 财政年份:
    2022
  • 资助金额:
    $ 37.09万
  • 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
  • 批准号:
    10741261
  • 财政年份:
    2022
  • 资助金额:
    $ 37.09万
  • 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
  • 批准号:
    10674894
  • 财政年份:
    2022
  • 资助金额:
    $ 37.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了